miR-625通过负向调控Resistin的表达抑制非小细胞肺癌细胞的恶性生物学行为及其机制  

miR-625 inhibits the malignant biological behavior of non-small cell lung cancer cells by negatively regulating Resistin expression and its mechanisms

作　　者：张建庆[1] 章恒[1] ZHANG Jianqing;ZHANG Heng(The First Department of Radiotherapy,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,Xinjiang,China)

机构地区：[1]新疆维吾尔自治区人民医院放疗一科,新疆乌鲁木齐830001

出　　处：《中国肿瘤生物治疗杂志》2020年第5期477-486,共10页Chinese Journal of Cancer Biotherapy

基　　金：新疆维吾尔自治区自然科学基金资助项目(No.2019D01C108)。

摘　　要：目的:探究miR-625和Resistin对NSCLC细胞增殖、侵袭、迁移及裸鼠移植瘤生长的影响及其可能的机制。方法:qPCR实验检测80例NSCLC及癌旁组织(标本收集自2018年3月至2019年10月于新疆维吾尔自治区人民医院手术治疗的NSCLC患者)和4种细胞系中miR-625与Resistin的表达,生物信息学预测两者的靶向关系并用双荧光素酶基因报告实验进行验证;通过脂质体转染技术在NSCLC细胞中过表达或抑制miR-625及Resistin表达,实验分为miR-625 mimic组、miR-625 inhibitor组、si-Resisitin组、miR-625 inhibitor+si-Resisitin组和NC组,利用CCK-8、Transwell及划痕实验检测miR-625与Resistin对NSCLC细胞增殖、侵袭及迁移的影响,Western blotting实验检测两者对NSCLC细胞中EMT相关的PI3K/AKT/Snail通路蛋白表达的影响,裸鼠成瘤实验观察两者对A549细胞移植瘤生长的影响。结果:miR-625在NSCLC组织和4种细胞系中呈低表达、Resistin呈高表达(均P<0.01),两者表达水平呈负相关(r=-0.7183,P<0.01),且Resistin的表达与NSCLC分化程度、临床分期及淋巴结转移相关。Resistin是miR-625的靶基因。在NSCLC细胞系A549和H226的增殖、侵袭、迁移能力及裸鼠移植瘤的生长方面,与Blank组和NC组相比,miR-625 mimic组与si-Resistin组能力均显著降低(均P<0.05),miR-625 inhibitor组显著提高(均P<0.05);miR-625 inhibitor+si-Resistin组显著低于miR-625 inhibitor组(均P<0.05);NC组与miR-625 inhibitor+si-Resistin组之间无显著差异(均P>0.05);p-AKT、p-PI3K、Snail、Twist1、Vimentin等蛋白表达变化也有相同的趋势(均P<0.05),E-cadherin蛋白表达则发生相反的改变(P<0.05)。结论:miR-625在NSCLC组织和细胞中均呈低表达,其能负向调控Resistin表达从而抑制NSCLC细胞的增殖、侵袭和迁移及裸鼠移植瘤生长,其机制可能与PI3K/AKT/Snail信号通路有关。Objective: To investigate the effects of miR-625 and Resistin on the proliferation, invasion and migration of NSCLC cells as well as the growth of transplanted tumors in nude mice and their possible mechanisms. Methods: qPCR was used to detect the expression of miR-625 and Resistin in 80 pairs of NSCLC and corresponding para-cancerous tissues(specimens collected from NSCLC patients who were surgically treated in Xinjiang Uygur Autonomous Region People’s Hospital from March 2018 to October2019) and four cell lines. Bioinformatics was adopted to predict the targeting relationship between miR-625 and Resistin, which was then verified by Dual luciferase gene reporter experiment. Overexpression or inhibition of miR-625 and Resistin in NSCLC cells was achieved with lipofection transfection technology, and the experimental cells were divided into miR-625 mimic group, miR-625 inhibitor group, si-Resisitin group, miR-625 inhibitor+si-Resisitin group and NC group. The effects of miR-625 and Resistin on proliferation, invasion and migration of NSCLC cells were detected by CCK-8, Transwell and Scratch test, respectively. Western blotting was used to detect the effects of miR-625 and Resistin on the expressions of PI3 K/AKT/Snail pathway proteins related with EMT in NSCLC cells. A549 cell transplanted tumor model was constructed in nude mice to observe the effect of miR-625 and Resistin on the growth of xenografts. Results: Compared with para-cancerous tissues, miR-625 showed low expression while Resistin showed high expression in NSCLC tissues and four cell lines(both P<0.01), and the two were negatively correlated(r=-0.7183,P<0.01). The expression of Resistin was related to the degree of NSCLC differentiation, clinical stage and lymph node metastasis. Resistin was a target gene of miR-625. Compared with the Blank group and NC group, the proliferation, invasion and migration of NSCLC cell lines A549 and H226, as well as the growth of transplanted tumors in nude mice in the miR-625 mimic group and the si-Resistin group were

关 键 词：miR-625 RESISTIN 非小细胞肺癌 A549细胞 H226细胞 增殖 侵袭 迁移 PI3K/AKT/Snail 

分 类 号：R734.2[医药卫生—肿瘤] R730.2[医药卫生—临床医学]